Understand the source comparison
Best Peptides for Ankylosing Spondylitis: Research Comparison
Thymalin Immunomodulation via thymic peptide bioregulation Restores CD4+/CD8+ T-cell balance and increases regulatory T-cell populations that suppress autoimmune inflammation 5–10mg daily subcutaneous for 10–20 days Preclinical autoimmune models + limited huma
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Immunomodulation via thymic peptide bioregulation
- Restores CD4+/CD8+ T-cell balance and increases regulatory T-cell populations that suppress autoimmune inflammation
- 5–10mg daily subcutaneous for 10–20 days
- Preclinical autoimmune models + limited human trials in mixed autoimmune cohorts
- Strongest immune regulation mechanism but lacks AS-specific human data. Best suited for addressing T-cell dysregulation upstream of cytokine production.
- BPC-157
- Tissue repair and angiogenesis
- Promotes VEGF expression and fibroblast migration to damaged entheses; reduces IL-6 and IL-1beta at inflammation sites
- 200–500 mcg daily subcutaneous
- Strong rodent arthritis models; no human AS trials
- Most robust preclinical evidence for joint tissue repair. Mechanism aligns well with entheseal damage but lacks validation in axial spondyloarthritis.
- TB-500
- Cytokine modulation and tissue remodeling
- Upregulates beta-actin for cell migration; suppresses IL-17 (critical AS cytokine) in inflammatory models
- 2–10mg weekly subcutaneous
- Moderate rodent arthritis models; anecdotal human use in sports medicine
- IL-17 suppression is mechanistically relevant to AS, but evidence base is weaker than BPC-157. Longer dosing intervals may improve protocol adherence.
- KPV (tripeptide)
- Anti-inflammatory via melanocortin pathway
- Activates melanocortin receptors to reduce NF-kappaB signaling and pro-inflammatory cytokine release
- 1–5mg daily oral or subcutaneous
- Emerging preclinical data; minimal human trials
- Novel mechanism but very early-stage evidence. Oral bioavailability is poor. Subcutaneous administration required for systemic effect.